By Counterforce Health Team in Prolastin-C (alpha1-proteinase inhibitor) —

How to Get Prolastin-C (Alpha1-Proteinase Inhibitor) Covered by Cigna in California: Complete Guide to Prior Authorization and Appeals

Answer Box: Getting Prolastin-C Covered by Cigna in California

Cigna requires prior authorization for Prolastin-C with specific clinical criteria: age ≥18, serum AAT <11 μM (80 mg/dL), confirmed emphysema on imaging, FEV1 30-65% predicted, and no tobacco use. Submit PA via CoverMyMeds with complete documentation. If denied, file internal appeal within 180 days, then request California's Independent Medical Review (IMR) through DMHC for binding external review. First step today: Contact your prescriber to order serum AAT level and spirometry if not current.

Table of Contents

  1. Patient Profile: Who Qualifies for Prolastin-C
  2. Pre-Authorization Preparation
  3. Submission Process
  4. Initial Outcome: Approval or Denial
  5. Appeals Process in California
  6. Resolution and Coverage Terms
  7. Common Pitfalls and Solutions
  8. California-Specific Resources
  9. FAQ

Patient Profile: Who Qualifies for Prolastin-C

Meet Sarah, a 42-year-old California resident with alpha1-antitrypsin (AAT) deficiency and emphysema. After years of progressive shortness of breath, her pulmonologist recommended Prolastin-C augmentation therapy. Here's what made her eligible under Cigna's coverage policy IP-0387:

Coverage Criteria Checklist

  • Age: ≥18 years ✓
  • Serum AAT level: <11 μM (80 mg/dL) ✓
  • Lung disease: Emphysema confirmed on high-resolution CT ✓
  • Lung function: FEV1 45% predicted (within 30-65% range) ✓
  • Tobacco status: Non-smoker for 2+ years ✓
Note: While Cigna's policy doesn't explicitly require Pi*ZZ genotyping, having this severe deficiency genotype documented strengthens your case.

Pre-Authorization Preparation

Sarah's pulmonologist gathered comprehensive documentation before submitting the prior authorization request:

Essential Documentation

Document Type Specific Requirements Where to Find
Lab Results Serum AAT <11 μM (80 mg/dL) Recent blood work within 6 months
Spirometry Pre-bronchodilator FEV1 30-65% predicted Pulmonary function test report
Imaging High-resolution CT showing basilar emphysema Radiology report
Clinical Notes Diagnosis, symptoms, tobacco history Provider documentation
Prescription Prolastin-C 60 mg/kg weekly IV Electronic or written Rx

Medical Necessity Letter Components

Sarah's doctor included these key elements in the medical necessity letter:

  1. Clinical presentation: Progressive dyspnea, reduced exercise tolerance
  2. Diagnostic confirmation: Severe AAT deficiency with emphysema
  3. Treatment rationale: Evidence-based augmentation therapy per FDA labeling
  4. Monitoring plan: Quarterly assessments, annual spirometry

Submission Process

Step-by-Step Submission

  1. Complete PA form: Use Cigna's Alpha1-Proteinase Inhibitor PA form
  2. Submit via CoverMyMeds: Electronic submission through provider portal
  3. Include attachments: Medical necessity letter, labs, imaging, clinical notes
  4. Verify receipt: Confirm submission within 24-48 hours
Tip: Cigna prefers Glassia and Prolastin-C over Zemaira as of 2026. If switching from Zemaira, document any tolerance issues with preferred agents.

Site of Care Considerations

Under Cigna's site of care policy PH-1605, home infusion through Accredo Specialty Pharmacy is preferred unless medical necessity requires hospital-based administration.

Initial Outcome: Approval or Denial

If Approved

Sarah received 1-year approval for Prolastin-C with these terms:

  • Dosing: 60 mg/kg weekly IV infusion
  • Site of care: Home infusion via Accredo
  • Monitoring: Quarterly provider assessments
  • Renewal: Submit updated documentation 30 days before expiration

Common Denial Reasons

Denial Reason Solution
Incomplete documentation Submit missing labs, imaging, or clinical notes
Non-preferred agent Request formulary exception or try preferred alternative
Site of care restriction Provide medical necessity for requested setting
Insufficient lung disease Include high-resolution CT and spirometry reports

Appeals Process in California

California offers robust appeal rights through two regulatory agencies depending on your plan type.

Internal Appeals with Cigna

  • Timeline: 180 days from denial notice
  • Process: Submit written appeal with additional evidence
  • Expedited option: Available for urgent medical situations
  • Documentation: Include peer-reviewed studies, treatment guidelines, specialist recommendations

California Independent Medical Review (IMR)

After exhausting internal appeals, California residents can request binding external review:

DMHC-Regulated Plans (Most HMOs)

  • Contact: DMHC Help Center at (888) 466-2219
  • Timeline: 45 days for standard review, 7 days for expedited
  • Success rate: Approximately 46-55% of medical necessity denials are overturned
  • Cost: Free to patients

CDI-Regulated Plans (Some PPOs)

  • Contact: CDI Consumer Hotline at (800) 927-4357
  • Process: Similar to DMHC but through Insurance Department
From our advocates: "We've seen several AAT deficiency cases succeed at IMR when initial denials cited 'experimental' status. The key was submitting FDA approval documentation and established treatment guidelines showing Prolastin-C as standard care for severe deficiency."

Building a Strong Appeal

When Sarah's initial request was denied for "insufficient documentation," her team submitted:

  1. Updated medical necessity letter with specific citations
  2. Peer-reviewed studies on AAT augmentation therapy efficacy
  3. Treatment guidelines from Alpha-1 Foundation and ATS/ERS
  4. Comparative analysis showing failed response to bronchodilators alone

Resolution and Coverage Terms

Sarah's appeal was successful after providing additional evidence of disease progression. Her final approval included:

  • Coverage period: 12 months with renewal option
  • Authorized site: Home infusion through Accredo
  • Monitoring requirements: Quarterly clinical assessments
  • Copay assistance: Manufacturer copay card reduced out-of-pocket costs

Ongoing Management

Counterforce Health helps patients like Sarah navigate complex prior authorization requirements by analyzing denial letters and crafting targeted appeals with evidence-based rebuttals. The platform identifies specific denial reasons and aligns responses to payer policies, improving approval rates for specialty medications.

Common Pitfalls and Solutions

Documentation Gaps

  • Problem: Missing or outdated lab values
  • Solution: Ensure AAT level is within 6 months of request

Formulary Changes

  • Problem: Prolastin-C moved to non-preferred status
  • Solution: Document medical necessity for specific brand or consider preferred alternatives

Site of Care Restrictions

  • Problem: Denial for home infusion
  • Solution: Provide clinical justification or accept alternative setting

California-Specific Resources

Regulatory Assistance

  • DMHC Help Center: (888) 466-2219 for HMO appeals
  • CDI Consumer Hotline: (800) 927-4357 for PPO appeals
  • Health Consumer Alliance: Non-profit patient advocacy

Financial Assistance

  • Grifols Patient Assistance Program: Income-based support
  • Alpha-1 Foundation: Educational resources and advocacy
  • California Prescription Drug Discount Program: State-sponsored savings

For complex cases requiring expert appeal assistance, Counterforce Health's platform specializes in turning insurance denials into successful approvals by crafting evidence-backed appeals tailored to specific payer policies.

FAQ

How long does Cigna prior authorization take in California? Standard PA decisions are typically made within 72 hours for urgent requests and 15 days for non-urgent requests.

What if Prolastin-C is non-formulary on my plan? Request a formulary exception with medical necessity documentation explaining why preferred alternatives are inappropriate.

Can I request an expedited appeal? Yes, if your condition requires urgent treatment. Contact Cigna member services to initiate expedited review.

Does step therapy apply if I've failed other AAT products? Document previous failures or intolerances to preferred agents (Glassia) when requesting Prolastin-C.

What happens if my internal appeal is denied? California residents can request Independent Medical Review (IMR) for binding external review at no cost.

How much does Prolastin-C cost without insurance? Annual costs typically exceed $80,000, with some studies showing average payer costs around $127,000 per year.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Coverage decisions depend on individual plan benefits and medical circumstances. Always consult with your healthcare provider and insurance plan for specific guidance regarding your situation.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.